Fillers
4 min readThe Filler-Dissolving Boom: Elective Hyaluronidase in 2026
Educational reading for licensed practitioners — not clinical or injection guidance.
For years, hyaluronidase was discussed almost entirely as an emergency drug — the enzyme you reach for when a vascular occlusion threatens tissue. In 2026 it has a second, fast-growing role: elective dissolving. A generation of patients who filled enthusiastically in the 2010s now want some of it taken back out, and "reversal" has quietly become a treatment category of its own.
What Is Driving the Demand
Several trends have converged. Migration — filler that has drifted from where it was placed, most visibly around the lips and tear troughs — has become a widely discussed concern, amplified by social media before-and-afters. So has overfilling: the "pillow face" or overly projected look that reads as done rather than refreshed. At the same time, the aesthetic mood has shifted towards restraint and skin quality over volume, and many patients now see a clean baseline as the first step, not filling on top of old product. Dissolving to reset — and sometimes to stop altogether — is part of the same "less is more" turn.
What Hyaluronidase Can and Cannot Do
Hyaluronidase breaks down hyaluronic acid, so it can address HA fillers such as the Juvederm, Restylane and Teosyal families. What it cannot do is dissolve non-HA products: calcium hydroxylapatite, poly-L-lactic acid and permanent fillers are unaffected by the enzyme. This makes an accurate history essential — knowing exactly what was injected, and ideally which product and when, before attempting to reverse anything. Dissolving what you assume is HA when it is not wastes time and misleads the patient.
It is also worth being clear that elective dissolving of filler is an off-label use of the enzyme in most settings, carried out on clinical judgement. It is not a casual add-on.
Managing Expectations
Patients often arrive expecting an eraser. The reality is more nuanced:
- Results are not always instant or complete in a single session; more than one treatment is sometimes needed.
- Hyaluronidase can affect the patient's own native HA in the area as well as the injected product, and the tissue may look temporarily flatter or more deflated before it settles.
- Allergic reactions to the enzyme are possible, so many practitioners consider a patch test before elective use, particularly in atopic patients.
- After dissolving, the skin needs time to recover before any decision about refilling.
Setting these expectations up front prevents the disappointment that comes from imagining dissolving as a clean undo button.
The "Dissolve and Refill" Trap
One temptation deserves a warning: dissolving and immediately refilling in the same visit. Beyond the practical difficulty of judging a natural baseline through residual swelling, it risks perpetuating the very cycle — the "filler fatigue" of endless topping-up — that many patients are trying to escape. A more considered approach lets the area recover fully, reassesses the actual tissue, and then decides whether any HA filler is warranted at all, often in smaller quantity than before. Reversal is an opportunity to reset the plan, not just the product.
A Word on Safety Culture
The elective boom has a useful side effect: it normalises having hyaluronidase in every clinic and being fluent in its use. That fluency is exactly what saves tissue in a real vascular emergency. But the two uses must not blur — elective dissolving should never draw down the ring-fenced emergency stock, and emergency dosing follows accredited protocols rather than elective habits. Competence in one supports readiness in the other, provided the boundary is respected.
Consent and Documentation
Because elective dissolving is generally an off-label use with its own risks — allergy, loss of native HA, an unpredictable end point — informed consent matters as much as it does for the original filler. Patients should understand that the result may be gradual, that more than one session can be needed, and that the area may look temporarily deflated before it settles. Documenting the discussion, the product used and the patient's expectations protects both parties, and photographs before and after help manage the inevitable question of "has it all gone?" Treating reversal with the same rigour as any other procedure keeps the growing demand safe rather than casual.
The Takeaway
Elective dissolving with hyaluronidase has grown from an emergency measure into a treatment in its own right, driven by migration, overfilling and a broader move towards restraint. Used well — on HA only, with an accurate history, realistic expectations and no rushed refill — it lets patients reset rather than merely add. Explore genuine, traceable product across the dermal fillers range, and keep dissolving as a considered step, not a reflex.